SETD1A and prostate carcinoma: Particularly, the expression of SETD1A is significantly correlated with the survival rate of prostate cancer patients, and the high expression of the SETD1A-FOXM1 pair is highly correlated with a poor prognosis, suggesting that it can be used as an important marker for predicting the proliferation and prognosis of mCRPC [143].